EUVIMEDObjevte EUVIMED
Crossref

Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation

Rong Li, Jiangli Lu, Peijin Wang, Yulan Zhao, Yi Yang, Jianlin Jiao, Zhongyi Qian, Limei Wang, Hong Zheng iD

Cell Biochemistry and Function · 2025

DOI: 10.1002/cbf.70108 ↗

At a glance

Journal article in Cell Biochemistry and Function, 2025. Written by Rong Li and 8 co-authors. Institution: Deparment of Laboratory Animal Science, Kunming Medical University, Kunming, Yunnan, P. R. China. Major MEDLINE topics: Phosphatidylinositol 3-Kinases, Diabetes Mellitus, Type 2, Glycogen Synthase Kinase 3 beta, Osteoblasts. 43 references. Funded by: The study was supported by the National Natural Science Foundation of China (No. 82460164); Applied Basic Research Key Project of Yunnan Province (No. 202201AY….

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Osteoking (OK) exerts bone formation‐promoting effects on menopausal osteoporosis and osteoporotic fractures. However, it remains to be determined whether OK ameliorates type 2 diabetic osteoporosis (T2DOP) via PI3K/AKT/GSK‐3β pathway activation. Thus, the T2DOP animal model was established in db/db mice in this study. Microcomputed tomography (micro‐CT) analysis revealed that OK significantly increased bone strength, improved bone metabolism, and promoted bone formation. GS and p‐GSK‐3β expression levels were increased in OK group as compared with db/db group by western blot analysis. IL‐6, IL‐17A, IFN‐γ, TNF‐α, and IL‐1β were lower levels in the OK group compared to the db/db group, nevertheless, the IL‐10 level was significantly higher. Furthermore, an in vitro cells model was constructed by stimulating with high glucose (HG, 30 mM). ALP protein was significantly elevated in the OK treatment group. Administration of OK at 0.288 mg/mL significantly increased p‐AKT/AKT expression, while, combined with LY294002, an inhibitor of PI3K, OK significantly reduced the expression levels of p‐PI3K/PI3K, p‐AKT/AKT, and p‐GSK‐3β/GSK‐3β. In conclusion, this study reveals OK exhibits efficacy against T2DOP in db/db mice by promoting osteogenesis of preosteoblast MC3T3‐E1 cells through PI3K/AKT/GSK‐3β pathway regulation.

Subjects

MeSH terms (MEDLINE)

Phosphatidylinositol 3-KinasesDiabetes Mellitus, Type 2Glycogen Synthase Kinase 3 betaOsteoblastsOsteoporosisSignal TransductionCell DifferentiationAnimalsProto-Oncogene Proteins c-aktMiceMice, Inbred C57BLX-Ray MicrotomographyDisease Models, AnimalOsteogenesis

Author keywords

OsteokingPI3K/AKT/GSK‐3β pathwayosteoblastspreosteoblasttype 2 diabetes osteoporosis

Substances

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesGlycogen Synthase Kinase 3 beta

Authors and institutions

  • Deparment of Laboratory Animal Science, Kunming Medical University, Kunming, Yunnan, P. R. China.
  • Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan, P. R. China.
  • School of Basic Medical Sciences, Kunming Medical University, Kunming, Yunnan, P. R. China.

ORCID profiles: Hong Zheng

Funding

  • The study was supported by the National Natural Science Foundation of China (No. 82460164); Applied Basic Research Key Project of Yunnan Province (No. 202201AY…

Cite

APA

Li, R., Lu, J., Wang, P., Zhao, Y., Yang, Y., Jiao, J., Qian, Z., Wang, L., & Zheng, H. (2025). Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70108

Vancouver

Li R, Lu J, Wang P, Zhao Y, Yang Y, Jiao J, et al. Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation. Cell Biochemistry and Function. 2025. doi:10.1002/cbf.70108

BibTeX
@article{Li2025,
  author = {Li, Rong and Lu, Jiangli and Wang, Peijin and Zhao, Yulan and Yang, Yi and Jiao, Jianlin and Qian, Zhongyi and Wang, Limei and Zheng, Hong},
  title = {Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation},
  journal = {Cell Biochemistry and Function},
  year = {2025},
  doi = {10.1002/cbf.70108}
}
Start for free →